Indications
Erosil (Erythromycin) is highly effective in treating a wide variety of clinical infections. Upper respiratory tract infections: tonsilitis, peritonsillar abscess, pharyngitis, laryngitis and sinusitis. It is also used for secondary infections in colds and influenza. Lower respiratory tract infections: tracheitis, and acute and chronic bronchitis. Ear infections: otitis media, otitis externa and mastoiditis. Eye infections: blepharitis and established trachoma. Skin and soft tissue infections: boils and carbuncles, impetigo, abscesses, pustular acne, paromychia, cellulitis and erysipelas. Gastrointestinal tract infections: cholecystitis and staphylococcal enterocolitis. Prophylaxis: pre and post-operative, trauma, burns and rheumatic fever. Other infections: osteomyelitis, diptheria, scarlet fever and whooping cough.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Erythromycin stops protein synthesis in susceptible organisms by blocking the translocation process. It binds specifically to the 50S subunit or 70S ribosome in these organisms, but it does not bind to the stable 80S mammalian ribosome. It is active against many Grampositive bacteria, some Gram-negative bacteria, and against mycoplasmas and chlamydia.
Absorption: Acid destroys erythromycin base, so it is given as a stable ester. Food slows the absorption of both the base and the esters. The stearate is hydrolyzed in the intestine and the free erythromycin is then absorbed.
Blood concentration: After an oral dose of 500 mg of the base or the stearate, peak serum concentrations of 0.9 to 1.4 mg/ml or 0.4 to 1.8 mg/ml respectively are reached in 1 to 4 hours.
Half-life: The serum half-life is 1.2 to 4 hours. In people with oliguria it is about 5 hours.
Distribution: Erythromycin spreads widely through body tissues and fluids, with some retention in the liver and spleen. Protein binding of erythromycin base is 73%. It enters the cerebrospinal fluid when the meninges are inflamed. It also crosses the placenta and is excreted in milk.
Excretion: 5 to 15% of the dose is excreted in the urine, and large amounts of the unchanged active substance are excreted in the bile.
Pregnancy & Breastfeeding
Clinical and laboratory studies have not shown any evidence of birth defects or toxicity in humans. Even so, erythromycin should be used with caution in pregnant and breastfeeding women, as it crosses the placenta and passes into breast milk.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.
Side Effects & Interactions
Side Effects
No side-effect data recorded yet.